menu
    • menu

    Company profile for AnaptysBio

    NEW Drugs in Dev: 6
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody gen...
    AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development of our proprietary product candidates.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AnaptysBioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10421 Pacific Center Court Suite 200 San Diego, CA 92121
    Telephone
    Telephone
    (858) 362-6295
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.anaptysbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Asia Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    Asia Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AnaptysBio Announces $100M Buyback, Business Update
    AnaptysBio Announces $100M Buyback, Business Update

    27 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/27/3263790/0/en/Anaptys-Announces-100-Million-Stock-Repurchase-Plan-and-Provides-a-Business-Update.html

    GLOBENEWSWIRE
    27 Mar 2026
    Share Share
    AnaptysBio Board Approve Spin-Off of First Tracks Biotherapeutics
    AnaptysBio Board Approve Spin-Off of First Tracks Biotherapeutics

    27 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/27/3263789/0/en/Anaptys-Board-of-Directors-Approves-Spin-Off-of-First-Tracks-Biotherapeutics.html

    GLOBENEWSWIRE
    27 Mar 2026
    Share Share
    First Tracks Biotherapeutics, Anaptys Spin-Off, Secures $145M
    First Tracks Biotherapeutics, Anaptys Spin-Off, Secures $145M

    27 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/27/3263788/0/en/First-Tracks-Biotherapeutics-the-Planned-Spin-Off-of-Anaptys-Secures-Commitments-of-145-Million-in-Private-Placement.html

    GLOBENEWSWIRE
    27 Mar 2026
    Share Share
    Anaptys Updates Business Separation, Reveals 2025 Financials
    Anaptys Updates Business Separation, Reveals 2025 Financials

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/03/3248938/0/en/Anaptys-Provides-Update-on-Business-Separation-and-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    Anaptys Announces Participation At Upcoming Investor Conferences
    Anaptys Announces Participation At Upcoming Investor Conferences

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3233465/0/en/Anaptys-Announces-Participation-at-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Anaptys Seeks Dismissal Of Tesaro's Anticipatory Breach Claim
    Anaptys Seeks Dismissal Of Tesaro's Anticipatory Breach Claim

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215854/0/en/Anaptys-Files-Motion-to-Dismiss-Tesaro-s-Claim-of-Anticipatory-Breach-of-Contract-in-Ongoing-Litigation-Against-Tesaro-a-GSK-subsidiary.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search